Retina Update - Feat. 12th Annual J. Arch McNamara, MD Memorial Lecture (12/3/2022 @ 8 a.m. ET)

GoToWebinar Livestream

With the emergence of new technologies, treatments, and clinical trial results, ophthalmologists need to understand how to incorporate these advances into clinical care. We will discuss latest advances in the management of inherited and acquired ophthalmic diseases and evidence for emerging therapies and screening modalities. Both didactic and case-based educational formats will be utilized to illustrate current trends in the management of complex and routine ophthalmic patients, taking into account diagnostics as well as nonsurgical and surgical treatment.

1. Discuss important new advances in the etiologies, diagnosis, and treatment/prevention of eye diseases.
2. Identify basic and clinical vision research that can be transformed into improved clinical care.
3. Assess the role of new technologies in the evaluation and treatment of eye diseases.
4. Describe factors that impact the effective delivery of the highest quality eye care for the public.
5. Identify clinical, scientific, and ethical issues confronting the profession.
6. Obtain information and tools through multiple facets to help ophthalmologists deliver high and efficient quality of care.

Credit Statement Designation
Wills Eye Hospital designates this Live Activity educational activity for a maximum of 4.00 AMA PRA Category 1 Credits^TM. Physicians should only claim the credit commensurate with the extent of their participation in the activity.

Mitigation of Relevant Financial Relationships

In compliance with the Standards for Integrity and Independence in Accredited Continuing Education set by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of Wills Eye Hospital that the information presented at CME activities will be commercially unbiased and based upon clinical and scientific evidence. To help participants make judgments about the presence of commercial bias, Wills Eye Hospital provides information that all individuals in a position to control the content of a CME activity (including faculty, planners, reviewers or others) have disclosed about all financial relationships they have with ineligible companies. All relevant financial relationships have been mitigated.

Ineligible companies are companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if the educational content an individual can control is related to the business lines or products of the ineligible company. The CME activity staff at Wills Eye Hospital report no financial relationships with ineligible companies.

Faculty Member Information

Role in activity

Name of Ineligible Company(s) / Nature of Relationship(s)

Ethan C Heck, MD
Wills Eye Hospital

Activity Coordinator

Nothing to disclose

Shaunna Lee, MD
Wills Eye Hospital

Activity Coordinator

Nothing to disclose

Sonia Mehta, MD
Wills Eye Hospital

Co-Director, Faculty

Yoshihiro Yonekawa, MD
Wills Eye Hospital / Mid Atlantic Retina

Co-Director, Faculty

Paid consultant-Alcon|Paid consultant-Allergan (Relationship has ended)|Paid consultant-Alimera Sciences (Relationship has ended)|Advisor-Pykus|Advisor-Tarsus

Arunan Sivalingam, MD

Course Director, Faculty

Nothing to disclose

Audina M. Berrocal, MD
Bascom Palmer Eye Institute

Faculty

Consulting Fee-Alcon|Consulting Fee-Dutch Ophthalmic USA|Consulting Fee-OCULUS Surgical, Inc.|Consulting Fee-Novartis (Relationship has ended)

Allen Chiang, MD
Wills Eye Hospital

Faculty

Grant or research support-Genentech|Consulting Fee-Genentech (Relationship has ended)|Grant or research support-Apellis Pharmaceuticals|Consulting Fee-Apellis Pharmaceuticals (Relationship has ended)

Michael N. Cohen, MD
Wills Eye Hospital / Mid Atlantic Retina

Faculty

Jordan Deaner, MD

Faculty

Maura Di Nicola, MD
Bascom Palmer Eye Institute

Faculty

Paid consultant-EyePoint Pharmaceuticals

Omesh P. Gupta, MD, MBA
Wills Eye Hospital

Faculty

Nothing to disclose

Julia A. Haller, MD
Wills Eye

Faculty

Membership on Advisory Committees or Review Panels, Board Membership, etc.-Bristol Myers Squibb|Stocks or stock options, excluding diversified mutual funds-Bristol Myers Squibb|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Opthea|Stocks or stock options, excluding diversified mutual funds-Opthea|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Eyenovia|Stocks or stock options, excluding diversified mutual funds-Eyenovia|Consulting Fee-Regeneron|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Aura Biosciences|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Lowy Medical Research Institute|Consulting Fee-Lowy Medical Research Institute|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Bionic Sight LLC|Consulting Fee-Bionic Sight LLC|Consulting Fee-KalVista (Relationship has ended)

Jason Hsu, MD
Wills Eye Physicians-Mid Atlantic Retina

Faculty

Consulting Fee-Iveric Bio|Consulting Fee-Gyroscope Therapeutics|Consulting Fee-Bausch + Lomb (Relationship has ended)|Grant or research support-Genentech|Grant or research support-Iveric Bio

Richard S. Kaiser, MD
Mid Atlantic Retina

Faculty

Nothing to disclose

Ajay E. Kuriyan, MD
Mid Atlantic Retina/Wills Eye Hospital

Faculty

Stocks or stock options, excluding diversified mutual funds-Recens medical|Consulting Fee-Alimera Sciences (Relationship has ended)|Grant or research support-Alcon|Grant or research support-Aderum Biotechnologies, Inc.|Consulting Fee-Allergan (Relationship has ended)|Consulting Fee-Bausch + Lomb (Relationship has ended)|Consulting Fee-Spark Therapeutics (Relationship has ended)|Consulting Fee-EyePoint Pharmaceuticals (Relationship has ended)|Consulting Fee-Genentech (Relationship has ended)|Grant or research support-Genentech (Relationship has ended)|Consulting Fee-Optos, Inc. (Relationship has ended)|Grant or research support-Annexon

Rebecca R Soares, MD
Wills Eye Hospital

Faculty

Nothing to disclose

Marc J. Spirn, MD
Mid Atlantic Retina

Faculty

Jayanth Sridhar, MD
Bascom Palmer Eye Institute

Faculty

Consulting Fee-Alcon|Consulting Fee-Dutch Ophthalmic USA|Consulting Fee-Genentech|Consulting Fee-Allergan (Relationship has ended)|Consulting Fee-Regeneron

Duo Xu, MD
Wills Eye Hospital

Faculty

Consulting Fee-Gyroscope Therapeutics|Advisor-Apellis|Consulting Fee-Bausch + Lomb

Carl D. Regillo, MD
Wills Eye-MAR

Faculty, Other Planning Committee Member

Consulting Fee-Allergan|Consulting Fee-Apellis Pharmaceuticals|Consulting Fee-EyePoint Pharmaceuticals|Consulting Fee-Genentech|Consulting Fee-Novartis|Consulting Fee-Ocugen|Consulting Fee-REGENXBIO, Inc.|Grant or research support-Regeneron

Ralph C. Eagle Jr., MD
Director
Wills Eye Hospital

Other Planning Committee Member

Stocks or stock options, excluding diversified mutual funds-Merck

Saturday, December 3, 2022